A Phase I safety study of hyperbaric oxygen therapy for amyotrophic lateral sclerosis

References

• Data Warehouse Centers for Disease Control. http://www.cdc.gov/nchs/datawh/statab/unpubd/mortabs/gmwki10.htm
   Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 33: 585–591.
   Google Scholar
• Groeneveld GJ, Van Kan HJ, Kalmijn S et al. Riluzole serum concentrations in patients with ALS: associations with side-effects and symptoms. Neurology 2003; 61: 1141–1143.
   Google Scholar
• Gurney ME, Pu H, Chiu AY et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science 1994; 264: 1772–1775.
   Google Scholar
• Bertamini M, Marzani B, Guarneri R et al. Mitochondrial oxidative metabolism in motor neuron degeneration (mnd) mouse central nervous system. Eur J Neurosci 2002; 16: 2291–2296.
   Google Scholar
• Gillingwater TH, Ribchester RR. The relationship of neuromus- cular synapse elimination to synaptic degeneration and pathol- ogy: insights from Wld(S) and other mutant mice. J Neurocytol 2003; 32: 863–881.
   PubMedGoogle Scholar
• Maddatu TP, Garvey SM, Shroeder DG et al. Transgenic rescue of neurogenic atrophy in the nmd mouse reveals a role for Ighmbp2 in dilated cardiomyopathy. Hum Mol Genet 2004; 13: 1105–1115.
   Google Scholar
• Papapetropoulos TA, Bradley WG. Spinal motor neurons in murine muscular dystrophy and spinal muscular atrophy. J Neurology Neurosurgery Psvchiatry 1972; 35: 60–65.
   PubMed Web of Science ®Google Scholar
• Dave KR, Prado R, Busto R et al. Hyperbaric oxygen therapy protects against mitochondrial dysfunction and delays onset of motor neuron disease in wobbler mice. Neuroscience 2003; 120: 113–120.
   Google Scholar
• Jaarsma D, Haasdijk ED, Grashorn JA et al. Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and prema- ture motor neuron death and accelerates motor neuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1. Neurobiol Dis 2000; 7: 623–643.
   Google Scholar
• Vielhaber S, Kunz D, Winkler K et al. Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis. Brain 2000; 123: 1339–1348.
   Google Scholar
• Swerdlow RH, Parks JK, Pattee G et al. Role of mitochondria in amyotrophic lateral sclerosis. ALS 2000; 1: 185–190.
   PubMed Web of Science ®Google Scholar
• Xu GP, Dave KR, Moraes CT et al. Dysfunctional mitochondrial respiration in the wobbler mouse brain. Neurosci Lett 2001; 300: 141–144.
   Google Scholar
• Finsterer J. Mitochondriopathy as a differential diagnosis of amyotrophic lateral sclerosis. ALS 2002; 3: 219–224.
   Google Scholar
• Menzies FM, Cookson MR, Taylor RW et al. Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain 2002; 125: 1522–1533.
   Google Scholar
• Mattiazzi M, D’Aurelio M, Gajewski CD et al. Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J Biol Chem 2002; 277: 29626–29633.
   Google Scholar
• Chung MJ, Suh YL. Ultrastructural changes of mitochondria in the skeletal muscle of patients with amyotrophic lateral sclerosis. Ultrastruct Pathol 2002; 26: 3–7.
   PubMed Web of Science ®Google Scholar
• Wiedemann FR, Manfredi G, Mawrin C et al. Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J Neurochem 2002; 80: 616–625.
   Google Scholar
• Cookson MR, Shaw PJ. Oxidative stress and motor neuron disease. Brain Pathol 1999; 9: 165–186.
   PubMed Web of Science ®Google Scholar
• Borthwick GM, Johnson MA, Ince PG et al. Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann Neurol 1999; 46: 787–790.
   Google Scholar
• Lee M, Hyun D, Jenner P et al. Effect of overexpression of wild- type and mutant Cu/Zn-superoxide dismutases on oxidative damage and antioxidant defences: relevance to Down’s syn- drome and familial amyotrophic lateral sclerosis. J Neurochem 2001; 76: 957–965.
   Google Scholar
• Rao AV, Balachandran B. Role of oxidative stress and anti- oxidants in neurodegenerative diseases. Nutr Neurosc 2002; 5: 291–309.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Munsat TL, for the World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyo- trophic lateral sclerosis. ALS 2000; 1: 293–299.
   Google Scholar
• Munsat TL, Andres PL, Finison L et al. The natural history of motor neuron loss in ALS. Neurology 1988; 38: 452–458.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci 1999; 169: 13–21.
   Google Scholar
• Hughes J. Pathology of amyotrophic lateral sclerosis. Adv Neurol 1982; 36: 61–73.
   PubMedGoogle Scholar
• Stampler N, Charatan M, Cederbaum JM, the ALS CNTF Treatment Study (ACTS) Group. Prognostic indicators of survival in ALS. Neurology 1998; 50: 66–72.
   Google Scholar
• Raudenbush SW, Bryk AS. Hierarchical Linear Models: Applica- tions and Data Analysis Methods, 2nd edn. Thousand Oaks, CA: Sage Publishing Co., 2002.
   Google Scholar
• Diggle PJ, Liang K, Zeger SL. Analysis of Longitudinal Data. NY: Oxford University Press, 1994.
   Google Scholar
• McCullagh P, Nelder JA. Generalized Linear Models, 2nd edn. Boca Raton, FL: Chapman & Hall/CRC, 1989.
   Google Scholar
• Andres PL, Finison LJ, Conlon T et al. Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis. Neurology 1988; 38: 405–408.
   Google Scholar
• Bruijn LI, Miller TM, Cleveland DW. Unravelling the mechan- isms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 2004; 27: 723–749.
   PubMed Web of Science ®Google Scholar
• Azzouz M, Ralph GS, Storkebaum E et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004; 429: 413–417.
   Google Scholar
• Lambrechts D, Storkebaum E, Morimoto M et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motor neurons against ischemic death. Nat Genet 2003; 34: 383–394.
   Google Scholar
• Skene JP, Cleveland DW. Hypoxia and Lou Gehrig. Nat Genet 2001; 28: 107–108.
   PubMed Web of Science ®Google Scholar
• Armon C. An evidence-based medicine approach to the evalua- tion of the role of exogenous risk factors in sporadic amyotro- phic lateral sclerosis. Neuroepidemiology 2003; 22: 217–228.
   PubMed Web of Science ®Google Scholar
• Delsite RL, Rasmussen LJ, Rasmussen AK et al. Mitochondrial impairment is accompanied by impaired oxidative DNA repair in the nucleus. Mutagenesis 2003; 18: 497–503.
   Google Scholar
• Migliore L, Molinu S, Naccarati A et al. Evaluation of cytogenetic and DNA damage in mitochondrial disease patients: effects of coenzyme Q10 therapy. Mutagenesis 2004; 19: 43–49.
   Google Scholar
• Goto S, Nakamura H, Morooka H et al. Role of reactive oxygen in phospholipase A2 activation by ischemia/reperfusion of the rat kidney. J Anesth 1999; 13: 90–93.
   Google Scholar
• Liu Y, Bao J, Lai H et al. Structural changes of neurons in hippocampus from infantile rats exposed to hyperbaric oxygen. Chin J Traumatol 2000; 3: 206–209.
   Google Scholar
• Hoagland RJ, Mendoza M, Armon C et al. Reliability of maximal voluntary isometric contraction testing in a multicenter study of patients with ALS. Muscle & Nerve 1997; 20: 691–695.
   Google Scholar
• The ALS CNTF Treatment Study Group. A double-blind contro- lled clinical trial of recombinant human ciliary neurotrophic factor (rHCNTF) in ALS. Neurology 1996; 46: 1244–1249.
   Google Scholar
• Bradley WGthe BDNF Study Group. A controlled trial of recombinant methionyl human BDNF in ALS (Phase III). Neurology 1999; 52: 1427–1433.
   Google Scholar
• Rosenfeld J, King RM, Smith JE. Oxandrolone in ALS: Preliminary analysis. ALS 2000; 4 (Suppl): 21–26.
   Google Scholar
• Miller RG, Moore DH, Gelinas DF et al. Phase III randomized trial of gabapentin in patients with ALS. Neurology 2001; 56: 843–848.
   Google Scholar
• Groeneveld GJ, Veldink JH, van der Tweel I et al. A randomized sequential trial of creatine in ALS. Ann Neurol 2003; 53: 437–445.
   Google Scholar
• Cudkowicz ME, Shefner JM, Schoenfeld DA et al. A randomized, placebo-controlled trial of topiramate in ALS. Neurology 2003; 61: 456–464.
   PubMed Web of Science ®Google Scholar